IPCA Laboratories

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

The company had posted a consolidated net profit after tax of Rs 161.34 crore in the same quarter previous fiscal, Ipca Laboratories said in a regulatory filing

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Lyka Labs is engaged in the manufacturing and marketing of injectables, lyophilized injectables and topical formulations

On Monday, Ipca Laboratories purchased 1.05 million equity shares representing 3.65 per cent stake in Lyka Labs at price of Rs 123 per share on the BSE via bulk deals

The board declared an interim dividend of Rs 8 per share

Motherson Sumi's stock has seen some buying interest in the past trading sessions and settled well above all its major moving averages on the daily time frame

Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

All that happened in the markets today.

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

Drug maker Ipca Laboratories is in the process of obtaining environmental clearance for a new manufacturing plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report.

The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing

According to Analysts at Phillip Capital, the company's revenues could grow 18 per cent year-on-year (YoY) to Rs 1,272.5 crore in June quarter of FY21

The level of 11,000 might act as support

14-17% top line growth estimate indicates 20% rise in earnings

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player

Outlook remains intact with India business on strong footing, exports supported by ingredient capabilities

Further rerating of stock will hinge on USFDA resolution

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens